细看康龙业绩其实可圈可点的,临床这块增速45%,比泰格要高,毛利也稳步提升。核心实验室业务也是稳步增长35%+,毛利也在提升。CDMO也增速37%...查看全文
医业观察星哥2023-01-27 18:53
有观点,有态度
这是医业观察的第1672-2期文章
来源:MedTrend医趋势、疾控中心、IVD从业者网等
雅培昨日(1月25日)发布2022年Q4及全年财务数据。
2022年全年:
雅培营收437亿美元,同比+1.3%;有机增长+6.4%。
雅培诊断业务收入为 165.8 亿美元,比 2021 年的 15...查看全文
Core Laboratories(CLB)今天 02:45
$Core Laboratories(CLB)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000950170-24-037061 Size: 16 KB 网页链接查看全文
Core Laboratories(CLB)今天 04:25
$Core Laboratories(CLB)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-037202 Act: 34 Size: 24 MB 网页链接查看全文
Core Laboratories(CLB)03-26 04:45
$Core Laboratories(CLB)$ 8-K Current report, item 5.02 Accession Number: 0000950170-24-035962 Act: 34 Size: 188 KB 网页链接查看全文
Core Laboratories(CLB)03-19 18:05
$Core Laboratories(CLB)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-033023 Act: 34 Size: 84 KB 网页链接查看全文
Core Laboratories(CLB)03-19 18:05
$Core Laboratories(CLB)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-033021 Act: 34 Size: 17 MB 网页链接查看全文
Core Laboratories(CLB)02-16 05:15
$Core Laboratories(CLB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-015883 Size: 6 KB 网页链接查看全文
Core Laboratories(CLB)02-15 19:05
$Core Laboratories(CLB)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-015483 Act: 34 Size: 17 MB 网页链接查看全文
Core Laboratories(CLB)02-16 05:15
$Core Laboratories(CLB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-015887 Size: 6 KB 网页链接查看全文
格隆汇1月11日丨昨天涨逾4%的康龙化成(3759.HK)今日再涨4.8%,报115.8港元;公司A股逆势涨近2%,报130.9元。公司此前公布,收购Recipharm旗下原料药生产基地。里昂研报指,公司在核心实验室服务方面拥有丰富的经验,并正在扩展到后期CMC(化学、制造和控制)... 网页链接
同花顺(300033)金融研究中心8月6日讯,有投资者向华大基因(300676)提问, 公司目前除了深圳总部,还有哪些地区总部?是否均建设有p3实验室?? 公司回答表示,您好,感谢您对华大基因的关注。公司总部位于中国深圳,在北京、天津... 网页链接
$Core Laboratories(CLB)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-037202 Act: 34 Size: 24 MB 网页链接
$Core Laboratories(CLB)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000950170-24-037061 Size: 16 KB 网页链接
$Core Laboratories(CLB)$ 8-K Current report, item 5.02 Accession Number: 0000950170-24-035962 Act: 34 Size: 188 KB 网页链接
$Core Laboratories(CLB)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-033023 Act: 34 Size: 84 KB 网页链接
$Core Laboratories(CLB)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-033021 Act: 34 Size: 17 MB 网页链接
$Core Laboratories(CLB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-015879 Size: 6 KB 网页链接
$Core Laboratories(CLB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-015883 Size: 6 KB 网页链接
$Core Laboratories(CLB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-015887 Size: 6 KB 网页链接
$Core Laboratories(CLB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-015888 Size: 6 KB 网页链接
$Core Laboratories(CLB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-015891 Size: 6 KB 网页链接